What is Pluristem?
Pluristem Therapeutics Inc. is a bio-technology company dedicated to the research, development, clinical trial, and manufacture of cell therapeutic products. Its primary focus lies in treating various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders, utilizing its proprietary placental expanded (PLX) based cell therapy platform. Key product candidates include PLX-PAD, which is undergoing Phase III trials for hip fracture recovery and Phase II trials for COVID-19-related acute respiratory distress syndrome, and PLX-R18, which has completed Phase I trials for hematopoietic recovery post-transplantation. The company's innovative approach also extends to collaborations with entities like NASA's Ames Research Center to explore cell therapies for space mission-related medical conditions.
How much funding has Pluristem raised?
Pluristem has raised a total of $199M across 14 funding rounds:
Other Financing Round
$250K
Other Financing Round
$1.2M
Grant
$4.2M
Grant
$2.9M
Stock Offering
$17M
Grant
$3.3M
Share Placement
$30M
Multiple Rounds
$49M
Stock Offering
$20M
Debt
$56.2M
Share Placement
$15M
Other Financing Round (2010): $250K, investors not publicly disclosed
Other Financing Round (2010): $1.2M, investors not publicly disclosed
Grant (2014): $4.2M supported by Israeli Ministry of Economy, Office of the Chief Scientist
Grant (2015): $2.9M featuring Israeli Ministry of Economy, Office of the Chief Scientist
Stock Issuance/Offering (2015): $17M, investors not publicly disclosed
Grant (2016): $3.3M with participation from Israeli Ministry of Economy, Office of the Chief Scientist
Share Placement (2016): $30M led by Innovative Medical Management
Stock Issuance/Offering (2017): $17.3M, investors not publicly disclosed
Grant (2017): $8.7M featuring Horizon 2020 Program
Grant (2017): $7.9M backed by Horizon 2020 Program
Stock Issuance/Offering (2017): $15.1M, investors not publicly disclosed
Stock Issuance/Offering (2019): $20M, investors not publicly disclosed
Debt (2020): $56.2M supported by European Investment Bank
Share Placement (2020): $15M, investors not publicly disclosed
Key Investors in Pluristem
European Investment Bank
The European Investment Bank (EIB) is the European Union's nonprofit long-term lending and finance institution, established in 1958 and headquartered in Luxembourg. It supports projects that align with EU policy objectives.
Israeli Ministry of Economy, Office of the Chief Scientist
The Israeli Ministry of Economy, Office of the Chief Scientist, is a governmental body that supports and funds research and development initiatives within Israel, fostering innovation across various technological sectors.
Innovative Medical Management
Innovative Medical Management appears to be an entity focused on the strategic and financial aspects of the medical and healthcare industry, likely involved in managing or investing in healthcare ventures.
What's next for Pluristem?
The substantial enterprise-level capital infusion, coupled with the recent strategic investment, positions Pluristem for accelerated growth and the advancement of its late-stage clinical trials. This backing is crucial for navigating the complex and capital-intensive process of drug development and regulatory approval. The company's focus on addressing critical unmet medical needs in areas like post-surgical recovery and ARDS suggests a strategic pivot towards commercialization readiness. Future endeavors will likely involve scaling manufacturing capabilities, expanding clinical trial reach, and potentially forging new strategic partnerships to bring its novel cell therapies to patients worldwide.
See full Pluristem company page
